Published in Drug Week, July 8th, 2005
Approved Canadian labeling, based on submission of published clinical studies, includes: temporary reduction in disturbances in skin sensation, increases in balance and reduction in fall risk (when used adjunctively with physical therapy) due to diabetic and other peripheral neuropathies.
Complications of this devastating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.